90985-77-6
Chemical Structure
Ginsenoside Ra3
- CAS No.: 90985-77-6
- Formula:C59H100O27
- Molecular Weight:1241.41
IUPAC Name: 2-((2-(3-((4,5-dihydroxy-6-(hydroxymethyl)-3-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-12-hydroxy-4,4,8,10,14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-methylhept-5-en-2-yl)oxy)-6-(((3,5-dihydroxy-6-(hydroxymethyl)-4-((3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-3,4,5-triol
InChIKey: QUNSGRLNZDSQJC-UHFFFAOYSA-N
SMILES: CC12C3(C(C(O)CC1C4(C(C(C)(C(OC5C(C(C(O)C(CO)O5)O)OC6OC(C(O)C(O)C6O)CO)CC4)C)CC2)C)C(C(CC/C=C(C)/C)(C)OC7OC(C(O)C(O)C7O)COC8C(C(C(O)C(CO)O8)OC9C(C(C(O)CO9)O)O)O)CC3)C
Biological Activity: Ginsenoside Ra3 is an OATP1B1/OATP1B3 inhibitor that blocks organic anion-transporting polypeptide-mediated cellular uptake. Ginsenoside Ra3 targets PIK3CA (the catalytic subunit of phosphatidylinositol 3-kinase) and PIK3CG (the catalytic subunit of phosphatidylinositol 3-kinase γ), both of which are components of the PI3K/Akt/mTOR pathway. Ginsenoside Ra3 targets AR, an androgen receptor that regulates PSA expression. Ginsenoside Ra3 inhibits platelet aggregation[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ginsenoside Ra3 | 99.91% | Ginsenoside Ra3 is an OATP1B1/OATP1B3 inhibitor that blocks organic anion-transporting polypeptide-mediated cellular uptake. Ginsenoside Ra3 targets PIK3CA (the catalytic subunit of phosphatidylinositol 3-kinase) and PIK3CG (the catalytic subunit of phosphatidylinositol 3-kinase γ), both of which are components of the PI3K/Akt/mTOR pathway. Ginsenoside Ra3 targets AR, an androgen receptor that regulates PSA expression. Ginsenoside Ra3 inhibits platelet aggregation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Olaleye OE, et al. Multiple circulating saponins from intravenous ShenMai inhibit OATP1Bs in vitro: potential joint precipitants of drug interactions. Acta pharmacologica Sinica. 2019 Jun;40(6):833-849.
- [2]. Li S, et al. Characterization of the Components and Pharmacological Effects of Mountain-Cultivated Ginseng and Garden Ginseng Based on the Integrative Pharmacology Strategy. Frontiers in pharmacology. 2021;12:659954.
- [3]. Peng Y, et al. The Multivariate Regression Statistics Strategy to Investigate Content-Effect Correlation of Multiple Components in Traditional Chinese Medicine Based on a Partial Least Squares Method. Molecules (Basel, Switzerland). 2018 Mar 01;23(3):545.
